mCRPC

Jul 15, 2025

Nanoscope’s MCO-010 Begins FDA Rolling Submission for Retinitis Pigmentosa; Bayer’s KERENDIA Approved by FDA for Heart Failure With Preserved Ejection Fraction; Klotho Neurosciences’ KLTO-202 Receives FDA Orphan Drug Designation for ALS; Trethera’s TRE-515 Granted FDA Fast Track Designation for Metastatic Prostate Cancer; Adcentrx’s ADRX-0405 Awarded FDA Orphan Drug Designation for Gastric Cancer

Oct 11, 2024

12 Breakthrough Prostate Cancer Drugs in Late-Stage Development 

Sep 25, 2024

Prostate Cancer Awareness Month: Early Detection Saves Lives!!

Jul 25, 2023

Gilead’s Magrolimab Plus Azacitidine for MDS; FDA Approveds VANFLYTA for Newly Diagnosed AML; FDA Awards Fast Track Designation to ARX517 mCRPC; EMA Rejects Mirati’s Krazati; Harmony Phase III Pitolisant Trial for PWS Patients; Belite Bio’s Phase 3 DRAGON Trial of Tinlarebant for STGD

Apr 25, 2023

Janssen’s AKEEGA Approval; FDA Approves Roche’s Polivy Combo for Frontline B-cell Lymphoma; Daiichi Sankyo’s Quizartinib for Adults With FLT3-ITD-Positive AML; bluebird bio BLA for lovo-cel for Patients with Sickle Cell Disease; Fast Track Designation for Lu-PNT2002 for mCRPC Treatment; FDA Orphan Drug Designation to XORTX’s Oxypurinol

Feb 24, 2023

A Quick Recap from ASCO GU 2023: Prostate and Urothelial Cancer Highlights

Mar 29, 2022

Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Feb 24, 2022

Early but strong clinical data of Arvinas’s ARV-110 in Men with mCRPC that support a potential path to accelerated approval

Feb 22, 2022

B7-H3, an emerging immune checkpoint molecule in metastatic CRPC and other cancers

Jan 14, 2022

Most Promising Oncological Drugs Expected to Launch in 2022

Newsletter/Whitepaper